HK1147748A1 - 作為 抑制劑的 -二氨基嘧啶的稠合雙環衍生物 - Google Patents
作為 抑制劑的 -二氨基嘧啶的稠合雙環衍生物Info
- Publication number
- HK1147748A1 HK1147748A1 HK11101845.2A HK11101845A HK1147748A1 HK 1147748 A1 HK1147748 A1 HK 1147748A1 HK 11101845 A HK11101845 A HK 11101845A HK 1147748 A1 HK1147748 A1 HK 1147748A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- alk
- met
- diaminopyrimidine
- fused bicyclic
- bicyclic derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85356206P | 2006-10-23 | 2006-10-23 | |
| PCT/US2007/022496 WO2008051547A1 (en) | 2006-10-23 | 2007-10-23 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1147748A1 true HK1147748A1 (zh) | 2011-08-19 |
Family
ID=39050187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK11101845.2A HK1147748A1 (zh) | 2006-10-23 | 2011-02-24 | 作為 抑制劑的 -二氨基嘧啶的稠合雙環衍生物 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8148391B2 (zh) |
| EP (2) | EP2222647B1 (zh) |
| JP (1) | JP5512274B2 (zh) |
| CN (1) | CN101535276B (zh) |
| AR (1) | AR063527A1 (zh) |
| AU (1) | AU2007309427B2 (zh) |
| CA (1) | CA2669111C (zh) |
| CL (1) | CL2007003049A1 (zh) |
| ES (2) | ES2555803T3 (zh) |
| HK (1) | HK1147748A1 (zh) |
| IL (1) | IL198150A (zh) |
| MX (1) | MX2009004426A (zh) |
| NZ (1) | NZ576425A (zh) |
| TW (1) | TWI432427B (zh) |
| WO (1) | WO2008051547A1 (zh) |
Families Citing this family (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| US8710045B2 (en) * | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
| CN101535276B (zh) * | 2006-10-23 | 2013-08-28 | 赛福伦公司 | 作为ALK和c-MET抑制剂的2,4-二氨基嘧啶稠合双环衍生物 |
| EP2091918B1 (en) * | 2006-12-08 | 2014-08-27 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| RS53588B1 (en) | 2006-12-08 | 2015-02-27 | Irm Llc | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS |
| CA2681015C (en) | 2007-03-16 | 2016-06-21 | The Scripps Research Institute | Inhibitors of focal adhesion kinase |
| TWI389893B (zh) | 2007-07-06 | 2013-03-21 | Astellas Pharma Inc | 二（芳胺基）芳基化合物 |
| EA017252B1 (ru) * | 2007-08-28 | 2012-11-30 | Айрм Ллк | Производные 2-бифениламино-4-аминопиримидина в качестве ингибиторов киназ |
| WO2009122180A1 (en) * | 2008-04-02 | 2009-10-08 | Medical Research Council | Pyrimidine derivatives capable of inhibiting one or more kinases |
| KR101238585B1 (ko) | 2008-04-07 | 2013-02-28 | 노파르티스 아게 | 단백질 키나제 억제제로서의 화합물 및 조성물 |
| WO2009127642A2 (en) * | 2008-04-15 | 2009-10-22 | Cellzome Limited | Use of lrrk2 inhibitors for neurodegenerative diseases |
| NZ589315A (en) | 2008-04-16 | 2012-11-30 | Portola Pharm Inc | 2,6-diamino-pyrimidin-5-yl-carboxamides as Spleen tryosine kinase (syk) or Janus kinase (JAK) inhibitors |
| US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| EA029131B1 (ru) | 2008-05-21 | 2018-02-28 | Ариад Фармасьютикалз, Инк. | Фосфорсодержащие производные в качестве ингибиторов киназы |
| PE20100087A1 (es) | 2008-06-25 | 2010-02-08 | Irm Llc | Compuestos y composiciones como inhibidores de cinasa |
| US8445505B2 (en) | 2008-06-25 | 2013-05-21 | Irm Llc | Pyrimidine derivatives as kinase inhibitors |
| ES2541528T3 (es) | 2008-11-19 | 2015-07-21 | Forum Pharmaceuticals Inc. | Tratamiento de trastornos cognitivos con (R)-7-cloro-N-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma |
| JP5762971B2 (ja) | 2008-12-03 | 2015-08-12 | プレシディオ ファーマシューティカルズ インコーポレイテッド | Ｈｃｖｎｓ５ａの阻害剤 |
| US20110071158A1 (en) * | 2009-03-18 | 2011-03-24 | Boehringer Ingelheim International Gmbh | New compounds |
| EP3009428B1 (en) | 2009-05-08 | 2018-02-21 | Astellas Pharma Inc. | Diamino heterocyclic carboxamide compound |
| PE20120324A1 (es) * | 2009-05-11 | 2012-04-17 | Envivo Pharmaceuticals Inc | Combinacion que comprende (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y donezepilo como moduladora de trastornos cognitivos |
| TW201100441A (en) | 2009-06-01 | 2011-01-01 | Osi Pharm Inc | Amino pyrimidine anticancer compounds |
| ES2668775T3 (es) * | 2009-06-10 | 2018-05-22 | Chugai Seiyaku Kabushiki Kaisha | Compuestos tetracíclicos |
| US20120142667A1 (en) * | 2009-06-10 | 2012-06-07 | Nigel Ramsden | Pyrimidine derivatives as zap-70 inhibitors |
| US8952034B2 (en) * | 2009-07-27 | 2015-02-10 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
| JP5539518B2 (ja) | 2009-08-14 | 2014-07-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ２−アミノ−５−トリフルオロメチルピリミジン誘導体の位置選択的調製 |
| US8933227B2 (en) | 2009-08-14 | 2015-01-13 | Boehringer Ingelheim International Gmbh | Selective synthesis of functionalized pyrimidines |
| WO2011058193A1 (en) * | 2009-11-16 | 2011-05-19 | Mellitech | [1,5]-diazocin derivatives |
| SI3029039T1 (en) | 2010-05-17 | 2018-04-30 | Forum Pharmaceuticals Inc. | Pharmaceutical formulations containing crystalline forms of (R) -7-chloro-N- (quinuclidin-3-yl) benzo (b) thiophene-2-carboxamide hydrochloride monohydrate |
| JP2013532627A (ja) | 2010-07-01 | 2013-08-19 | 武田薬品工業株式会社 | ｃＭＥＴ阻害剤とＨＧＦおよび／またはｃＭＥＴに対する抗体との組み合わせ |
| AU2011272787B2 (en) | 2010-07-02 | 2015-06-18 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
| US20120101108A1 (en) | 2010-08-06 | 2012-04-26 | Cell Signaling Technology, Inc. | Anaplastic Lymphoma Kinase In Kidney Cancer |
| MY160110A (en) | 2010-08-20 | 2017-02-28 | Chugai Pharmaceutical Co Ltd | Composition comprising tetracyclic compound |
| JP5006987B2 (ja) * | 2010-11-22 | 2012-08-22 | 中外製薬株式会社 | ４環性化合物を含む医薬 |
| WO2012074951A1 (en) | 2010-11-29 | 2012-06-07 | OSI Pharmaceuticals, LLC | Macrocyclic kinase inhibitors |
| US9834518B2 (en) | 2011-05-04 | 2017-12-05 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
| NZ716420A (en) | 2011-05-10 | 2017-05-26 | Gilead Sciences Inc | Fused heterocyclic compounds as sodium channel modulators |
| NO3175985T3 (zh) | 2011-07-01 | 2018-04-28 | ||
| TW201837023A (zh) | 2011-07-01 | 2018-10-16 | 美商基利科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
| EP2554544A1 (en) * | 2011-08-01 | 2013-02-06 | Almirall, S.A. | Pyridin-2(1h)-one derivatives as jak inhibitors |
| US8877760B2 (en) | 2011-11-23 | 2014-11-04 | Portola Pharmaceuticals, Inc. | Substituted pyrazine-2-carboxamide kinase inhibitors |
| BR112014011219B1 (pt) * | 2011-11-29 | 2022-08-23 | Genentech, Inc. | Derivados de aminopirimidina, seus usos, e composição farmacêutica |
| DK2822939T3 (en) * | 2012-03-06 | 2016-03-14 | Cephalon Inc | CONDENSED BICYCLEIC 2,4-DIAMINOPYRIMIDINE DERIVATIVES AS DUAL ALK AND FAK INHIBITORS |
| WO2013169401A1 (en) | 2012-05-05 | 2013-11-14 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
| WO2013169646A1 (en) | 2012-05-08 | 2013-11-14 | Envivo Pharmaceuticals, Inc. | Methods of maintaining, treating or improving cognitive function |
| KR101446742B1 (ko) | 2012-08-10 | 2014-10-01 | 한국화학연구원 | Ｎ2,ｎ4-비스(4-(피페라진-1-일)페닐)피리미딘-2,4-디아민 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
| CN103664903A (zh) * | 2012-09-04 | 2014-03-26 | 中国科学院上海药物研究所 | 苯氮卓类化合物及其制备方法和用途 |
| HUE040055T2 (hu) | 2012-09-25 | 2019-02-28 | Chugai Pharmaceutical Co Ltd | RET inhibitor |
| US9206166B2 (en) | 2012-11-06 | 2015-12-08 | SHANGHAI iNSTITUTE OF MATERIA MEDICA ACADEMY OF SCIENCES | Certain protein kinase inhibitors |
| CN104968667B (zh) * | 2013-02-05 | 2017-06-20 | 山东轩竹医药科技有限公司 | 四并环激酶抑制剂 |
| WO2014128235A1 (en) | 2013-02-22 | 2014-08-28 | F. Hoffmann-La Roche Ag | Methods of treating cancer and preventing drug resistance |
| DK2970205T3 (da) | 2013-03-14 | 2019-07-29 | Tolero Pharmaceuticals Inc | JAK2- og ALK2-inhibitorer og fremgangsmåder til anvendelse deraf |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| KR20160020502A (ko) | 2013-06-18 | 2016-02-23 | 노파르티스 아게 | 제약 조합물 |
| WO2015038868A1 (en) * | 2013-09-13 | 2015-03-19 | Cephalon, Inc. | Fused bicyclic 2,4-diaminopyrimidine derivatives |
| KR101656382B1 (ko) | 2014-02-28 | 2016-09-09 | 한국화학연구원 | 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물 |
| US10350214B2 (en) | 2014-04-25 | 2019-07-16 | Chugai Seiyaku Kabushiki Kaisha | Preparation containing tetracyclic compound at high dose |
| EP3135671B1 (en) | 2014-04-25 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Novel crystal of tetracyclic compound |
| WO2015170218A1 (en) | 2014-05-07 | 2015-11-12 | Pfizer Inc. | Tropomyosin-related kinase inhibitors |
| WO2015180685A1 (zh) * | 2014-05-30 | 2015-12-03 | 北京浦润奥生物科技有限责任公司 | Alk激酶抑制剂及其制备方法和应用 |
| EP3159338A4 (en) * | 2014-06-17 | 2018-01-24 | Korea Research Institute of Chemical Technology | Pyrimidine-2,4-diamine derivative and anticancer pharmaceutical composition comprising same as effective ingredient |
| TWI718102B (zh) | 2014-08-08 | 2021-02-11 | 日商中外製藥股份有限公司 | ４環性化合物的非晶質體 |
| KR101633722B1 (ko) | 2014-10-08 | 2016-06-28 | 한국화학연구원 | 4-(1-퍼롤-3,4-디카르복시아미드)피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
| CN105524045B (zh) * | 2014-10-22 | 2020-04-10 | 山东轩竹医药科技有限公司 | 四环类间变性淋巴瘤激酶抑制剂 |
| US10202368B2 (en) | 2014-12-01 | 2019-02-12 | Idorsia Pharmaceuticals Ltd. | CXCR7 receptor modulators |
| US10398774B2 (en) | 2014-12-09 | 2019-09-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Human monoclonal antibodies against AXL |
| WO2016100711A1 (en) * | 2014-12-18 | 2016-06-23 | The Broad Institute, Inc. | Modulators of hepatic lipoprotein metabolism |
| JP6741596B2 (ja) | 2015-01-16 | 2020-08-19 | 中外製薬株式会社 | 併用医薬 |
| WO2016135041A1 (en) | 2015-02-26 | 2016-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fusion proteins and antibodies comprising thereof for promoting apoptosis |
| KR101772134B1 (ko) | 2015-04-14 | 2017-08-29 | 한국화학연구원 | N2-(2-메톡시페닐)피리미딘 유도체, 이의 제조 방법 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
| KR101653571B1 (ko) | 2015-04-22 | 2016-09-05 | 한국화학연구원 | 4-(2-아미노-테트라하이드로나프탈렌닐)피리미딘 유도체, 이의 제조 방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
| CN105400143B (zh) * | 2015-12-11 | 2017-10-03 | 广州欣凯化工科技有限公司 | 一种木制品缝隙的修补组合物 |
| KR102206321B1 (ko) | 2016-01-15 | 2021-01-21 | 화이자 인코포레이티드 | 6,7,8,9-테트라하이드로-5H-피리도[2,3-d]아제핀 도파민 D3 리간드 |
| SG11201913517UA (en) | 2017-07-28 | 2020-02-27 | Yuhan Corp | Improved process for preparing aminopyrimidine derivatives |
| CN111032630B (zh) * | 2017-08-18 | 2022-12-16 | 北京韩美药品有限公司 | 一种化合物，其药物组合物及其用途及应用 |
| CN110240545B (zh) * | 2018-03-08 | 2022-04-26 | 迈克斯(如东)化工有限公司 | 一种2-(5-氟-2,4-二硝基苯氧)乙酸的制备方法 |
| TWI674931B (zh) * | 2018-03-13 | 2019-10-21 | 川尚股份有限公司 | 污染混合物的處理方法 |
| JP7149089B2 (ja) * | 2018-03-26 | 2022-10-06 | 株式会社日本触媒 | 含窒素複素環化合物およびスクアリリウム化合物の製造方法 |
| US11040038B2 (en) | 2018-07-26 | 2021-06-22 | Sumitomo Dainippon Pharma Oncology, Inc. | Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the same |
| IL281079B1 (en) | 2018-09-04 | 2024-08-01 | Chugai Pharmaceutical Co Ltd | Production method for a tetracyclic compound |
| CN109632773B (zh) * | 2019-01-08 | 2021-11-12 | 贵州大学 | 一种二氢硫辛酸琥珀酰转移酶抑制剂的筛选方法 |
| JP2022539208A (ja) | 2019-07-03 | 2022-09-07 | スミトモ ファーマ オンコロジー， インコーポレイテッド | チロシンキナーゼ非受容体１（ｔｎｋ１）阻害剤およびその使用 |
| US20240150356A1 (en) * | 2019-10-22 | 2024-05-09 | Alphala Co., Ltd. | Pyrimidine amide compounds and use thereof |
| CN110950797A (zh) * | 2019-12-06 | 2020-04-03 | 丽水绿氟科技有限公司 | 一种2-三氟甲基-3-氟-4-吡啶甲酸及其衍生物的制备方法 |
| CA3169286A1 (en) * | 2020-02-25 | 2021-09-02 | Dana-Farber Cancer Institute, Inc. | Potent and selective degraders of alk |
| CA3171776A1 (en) * | 2020-04-14 | 2021-10-21 | Shansong ZHENG | Tricyclic compounds as egfr inhibitors |
| WO2021239133A1 (zh) * | 2020-05-29 | 2021-12-02 | 南京正大天晴制药有限公司 | 作为axl抑制剂的嘧啶类化合物 |
| CN112213428A (zh) * | 2020-10-13 | 2021-01-12 | 辽宁科技大学 | 一种超临界co2中进行非催化乙酰基化反应及其在线检测方法 |
| WO2022147620A1 (en) * | 2021-01-07 | 2022-07-14 | Ontario Institute For Cancer Research (Oicr) | Thienyl and cycloalkyl aminopyrimidine compounds as inhibitors of nuak kinases, compositions and uses thereof |
| TW202246263A (zh) * | 2021-03-23 | 2022-12-01 | 大陸商杭州阿諾生物醫藥科技有限公司 | Ｈｐｋ１激酶抑制劑化合物 |
| WO2022214681A1 (en) | 2021-04-09 | 2022-10-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of anaplastic large cell lymphoma |
| CN115838383A (zh) * | 2021-09-22 | 2023-03-24 | 南京正大天晴制药有限公司 | 作为axl抑制剂的苯并环庚烷类化合物 |
| WO2023061434A1 (zh) * | 2021-10-14 | 2023-04-20 | 齐鲁制药有限公司 | 一种三环化合物的用途 |
| CN114133360A (zh) * | 2021-11-30 | 2022-03-04 | 南京工业大学 | 一种含氟苯并[d]-1,3-氧氮杂卓化合物及其合成方法 |
| CN114539104A (zh) * | 2022-03-09 | 2022-05-27 | 常州佳德医药科技有限公司 | 一种艾拉莫德中间体的制备方法 |
| CN115872995B (zh) * | 2022-12-27 | 2024-10-01 | 上海凌凯科技股份有限公司 | 一种吡唑并吡啶化合物及一种羧酸衍生物的制备方法 |
| WO2024206858A1 (en) | 2023-03-30 | 2024-10-03 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2297910A1 (en) | 1997-07-25 | 1999-02-04 | Smithkline Beecham Corporation | Vitronectin receptor antagonist |
| TR200002760T2 (tr) * | 1998-03-27 | 2000-12-21 | Janssen Pharmaceutica N.V. | HIV engelleyici pirimidin türevleri |
| GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| GB9914258D0 (en) | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
| US6906067B2 (en) | 1999-12-28 | 2005-06-14 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of TNF-α expression |
| GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| IL159120A0 (en) | 2001-05-29 | 2004-05-12 | Schering Ag | Cdk inhibiting pyrimidines, production thereof and their use as medicaments |
| US20030139435A1 (en) | 2001-06-26 | 2003-07-24 | Gulzar Ahmed | N-heterocyclic inhibitors of TNF-alpha expression |
| US7115617B2 (en) | 2001-08-22 | 2006-10-03 | Amgen Inc. | Amino-substituted pyrimidinyl derivatives and methods of use |
| US6939874B2 (en) | 2001-08-22 | 2005-09-06 | Amgen Inc. | Substituted pyrimidinyl derivatives and methods of use |
| WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| WO2003026665A1 (en) | 2001-09-26 | 2003-04-03 | Bayer Pharmaceuticals Corporation | 2-phenylamino-4-(5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, src kinase inhibitors |
| JP4460292B2 (ja) * | 2001-10-17 | 2010-05-12 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | ピリミジン誘導体、これらの化合物を含む医薬組成物、その使用及びその調製方法 |
| WO2003032994A2 (de) * | 2001-10-17 | 2003-04-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren |
| BR0213790A (pt) | 2001-11-01 | 2004-12-07 | Janssen Pharmaceutica Nv | Derivados de aminobenzamida como inibidores de glicogênio sintase cinase 3beta |
| US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| WO2003055489A1 (en) | 2001-12-21 | 2003-07-10 | Bayer Pharmaceuticals Corporation | 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| US7179826B2 (en) | 2002-03-15 | 2007-02-20 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
| DE60332604D1 (de) | 2002-03-15 | 2010-07-01 | Vertex Pharma | Azolylaminoazine als proteinkinasehemmer |
| ATE466580T1 (de) | 2002-03-15 | 2010-05-15 | Vertex Pharma | Azolylaminoazine als proteinkinasehemmer |
| WO2003095448A1 (en) | 2002-05-06 | 2003-11-20 | Bayer Pharmaceuticals Corporation | Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders |
| US7449456B2 (en) * | 2002-06-28 | 2008-11-11 | Astellas Pharma, Inc. | Diaminopyrimidinecarboxamide derivative |
| CN1678321A (zh) | 2002-07-29 | 2005-10-05 | 里格尔药品股份有限公司 | 用2,4－嘧啶二胺化合物治疗或者预防自体免疫性疾病的方法 |
| EP2476667B1 (en) | 2003-02-26 | 2014-07-16 | Sugen, Inc. | Aminoheteroaryl compounds as protein kinase inhibitors |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| US7504396B2 (en) | 2003-06-24 | 2009-03-17 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| US7037909B2 (en) | 2003-07-02 | 2006-05-02 | Sugen, Inc. | Tetracyclic compounds as c-Met inhibitors |
| US7122548B2 (en) | 2003-07-02 | 2006-10-17 | Sugen, Inc. | Triazolotriazine compounds and uses thereof |
| WO2005005378A2 (en) | 2003-07-02 | 2005-01-20 | Sugen, Inc. | Indolinone hydrazides as c-met inhibitors |
| WO2005006945A2 (en) | 2003-07-03 | 2005-01-27 | The Salk Institute For Biological Studies | Methods for treating neural disorders and compounds useful therefor |
| AU2004259012C1 (en) | 2003-07-23 | 2012-08-02 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
| US7442698B2 (en) | 2003-07-24 | 2008-10-28 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| EP1656372B1 (en) | 2003-07-30 | 2013-04-10 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases |
| DE602004032446D1 (de) | 2003-08-07 | 2011-06-09 | Rigel Pharmaceuticals Inc | 2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel |
| MXPA06001759A (es) | 2003-08-15 | 2006-05-12 | Novartis Ag | 2,4-pirimidinadiaminas utiles en el tratamiento de enfermedades neoplasticas, desordenes del sistema inmune e inflamatorios. |
| TWI339206B (en) | 2003-09-04 | 2011-03-21 | Vertex Pharma | Compositions useful as inhibitors of protein kinases |
| GB0321710D0 (en) | 2003-09-16 | 2003-10-15 | Novartis Ag | Organic compounds |
| AU2004272288B2 (en) | 2003-09-18 | 2008-11-13 | Novartis Ag | 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders |
| ES2651730T3 (es) | 2003-09-26 | 2018-01-29 | Exelixis, Inc. | Moduladores c-Met y métodos de uso |
| US7144889B2 (en) | 2003-10-16 | 2006-12-05 | Hoffman-La Roche Inc. | Triarylimidazoles |
| US7169781B2 (en) | 2003-10-17 | 2007-01-30 | Hoffmann-La Roche Inc. | Imidazole derivatives and their use as pharmaceutical agents |
| EP1694652A1 (en) | 2003-12-19 | 2006-08-30 | Rigel Pharmaceuticals, Inc. | Stereoisomers and stereoisomeric mixtures of 1-(2,4-pyrimidinediamino)-2-cyclopentanecarboxamide synthetic intermediates |
| GEP20084439B (en) | 2004-01-23 | 2008-07-25 | Amgen Inc | Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof |
| AU2005214352B2 (en) | 2004-02-14 | 2009-11-12 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| MXPA06009547A (es) | 2004-02-23 | 2007-01-26 | Dana Farber Cancer Inst Inc | Metodo para tratar el crecimiento celular anormal usando inhibidores de c-met y m-tor. |
| EP1730128A1 (en) | 2004-03-31 | 2006-12-13 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
| US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| TW200538453A (en) | 2004-04-26 | 2005-12-01 | Bristol Myers Squibb Co | Bicyclic heterocycles as kinase inhibitors |
| MXPA06013164A (es) | 2004-05-14 | 2007-02-13 | Pfizer Prod Inc | Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal. |
| BRPI0510963A (pt) | 2004-05-14 | 2007-11-20 | Pfizer Prod Inc | derivados pirimidina para o tratamento do crescimento anormal de células |
| CA2566531A1 (en) | 2004-05-18 | 2005-12-15 | Rigel Pharmaceuticals, Inc. | Cycloalkyl substituted pyrimidinediamine compounds and their uses |
| EP1598343A1 (de) | 2004-05-19 | 2005-11-23 | Boehringer Ingelheim International GmbH | 2-Arylaminopyrimidine als PLK Inhibitoren |
| US7521457B2 (en) | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
| GB0419160D0 (en) | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
| GB0419161D0 (en) | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
| GB2420559B (en) | 2004-11-15 | 2008-08-06 | Rigel Pharmaceuticals Inc | Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses |
| US8211929B2 (en) | 2004-12-30 | 2012-07-03 | Exelixis, Inc. | Pyrimidine derivatives as kinase modulators and method of use |
| WO2006128129A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
| SG137989A1 (en) | 2005-06-08 | 2008-01-28 | Rigel Pharmaceuticals Inc | Compositions and methods for inhibition of the JAK pathway |
| US20070032514A1 (en) | 2005-07-01 | 2007-02-08 | Zahn Stephan K | 2,4-diamino-pyrimidines as aurora inhibitors |
| MX2008000574A (es) | 2005-07-11 | 2008-03-14 | Sanofi Aventis | Nuevos derivados de 2,4-dianilinopirimidinas, la preparacion de los mismos, su uso como medicamentos, composiciones farmaceuticas y, en particular, como inhibidores ikk. |
| WO2007028445A1 (en) | 2005-07-15 | 2007-03-15 | Glaxo Group Limited | 6-indolyl-4-yl-amino-5-halogeno-2-pyrimidinyl-amino derivatives |
| KR100674813B1 (ko) | 2005-08-05 | 2007-01-29 | 일양약품주식회사 | Ｎ-페닐-2-피리미딘-아민 유도체 및 그의 제조방법 |
| MY167260A (en) | 2005-11-01 | 2018-08-14 | Targegen Inc | Bi-aryl meta-pyrimidine inhibitors of kinases |
| KR101060051B1 (ko) * | 2005-12-21 | 2011-08-29 | 화이자 프로덕츠 인크. | 비정상적인 세포 성장을 치료하기 위한 피리미딘 유도체 |
| TW200736232A (en) | 2006-01-26 | 2007-10-01 | Astrazeneca Ab | Pyrimidine derivatives |
| CA2640398A1 (en) | 2006-01-30 | 2007-08-09 | Exelixis, Inc. | 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and pharmaceutical compositions containing them |
| TW200804364A (en) | 2006-02-22 | 2008-01-16 | Boehringer Ingelheim Int | New compounds |
| US8258129B2 (en) | 2006-07-06 | 2012-09-04 | Boehringer Ingelheim International Gmbh | 4-heterocycloalkylpyri(mi)dines, process for the preparation thereof and their use as medicaments |
| CN101535276B (zh) * | 2006-10-23 | 2013-08-28 | 赛福伦公司 | 作为ALK和c-MET抑制剂的2,4-二氨基嘧啶稠合双环衍生物 |
| RS53588B1 (en) | 2006-12-08 | 2015-02-27 | Irm Llc | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS |
| EP2091918B1 (en) | 2006-12-08 | 2014-08-27 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
-
2007
- 2007-10-23 CN CN2007800394641A patent/CN101535276B/zh active Active
- 2007-10-23 AR ARP070104687A patent/AR063527A1/es not_active Application Discontinuation
- 2007-10-23 AU AU2007309427A patent/AU2007309427B2/en active Active
- 2007-10-23 TW TW096139772A patent/TWI432427B/zh not_active IP Right Cessation
- 2007-10-23 WO PCT/US2007/022496 patent/WO2008051547A1/en active Application Filing
- 2007-10-23 CL CL200703049A patent/CL2007003049A1/es unknown
- 2007-10-23 ES ES07861484.9T patent/ES2555803T3/es active Active
- 2007-10-23 CA CA2669111A patent/CA2669111C/en active Active
- 2007-10-23 JP JP2009534629A patent/JP5512274B2/ja active Active
- 2007-10-23 US US12/162,851 patent/US8148391B2/en active Active
- 2007-10-23 ES ES13173365.1T patent/ES2633318T3/es active Active
- 2007-10-23 MX MX2009004426A patent/MX2009004426A/es active IP Right Grant
- 2007-10-23 EP EP07861484.9A patent/EP2222647B1/en active Active
- 2007-10-23 NZ NZ576425A patent/NZ576425A/xx unknown
- 2007-10-23 EP EP13173365.1A patent/EP2684874B1/en active Active
-
2009
- 2009-04-16 IL IL198150A patent/IL198150A/en active IP Right Grant
-
2011
- 2011-02-24 HK HK11101845.2A patent/HK1147748A1/zh unknown
-
2012
- 2012-03-06 US US13/413,322 patent/US8552186B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2222647A1 (en) | 2010-09-01 |
| AU2007309427B2 (en) | 2013-02-28 |
| US8148391B2 (en) | 2012-04-03 |
| NZ576425A (en) | 2012-04-27 |
| IL198150A0 (en) | 2009-12-24 |
| US20090221555A1 (en) | 2009-09-03 |
| TW200833686A (en) | 2008-08-16 |
| EP2684874A1 (en) | 2014-01-15 |
| JP5512274B2 (ja) | 2014-06-04 |
| MX2009004426A (es) | 2009-08-12 |
| JP2010507665A (ja) | 2010-03-11 |
| AR063527A1 (es) | 2009-01-28 |
| TWI432427B (zh) | 2014-04-01 |
| CA2669111C (en) | 2016-04-12 |
| AU2007309427A1 (en) | 2008-05-02 |
| US20120165519A1 (en) | 2012-06-28 |
| IL198150A (en) | 2014-06-30 |
| ES2555803T3 (es) | 2016-01-08 |
| EP2684874B1 (en) | 2017-05-17 |
| EP2222647B1 (en) | 2015-08-05 |
| CN101535276A (zh) | 2009-09-16 |
| ES2633318T3 (es) | 2017-09-20 |
| CA2669111A1 (en) | 2008-05-02 |
| WO2008051547A1 (en) | 2008-05-02 |
| CL2007003049A1 (es) | 2008-05-16 |
| US8552186B2 (en) | 2013-10-08 |
| CN101535276B (zh) | 2013-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1147748A1 (zh) | 作為 抑制劑的 -二氨基嘧啶的稠合雙環衍生物 | |
| EG25942A (en) | Quinazolinedione derivatives as parp inhibitors | |
| IL196601A0 (en) | Pyrimidine derivatives and pharmaceutical compositions containing the same | |
| ZA200901593B (en) | Pyrimidines derivatives and their use as kinase inhibitors | |
| PT1926722E (pt) | Benzimidazoles substituídos como inibidores de quinases | |
| PL2004654T3 (pl) | Pochodne pirazolopirymidyny do stosowania jako antagonisty kinazy | |
| IL198171A0 (en) | Dihydropyridine derivatives useful as protein kinase inhibitors | |
| EP1885369A4 (en) | FUSED HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF AND USES THEREOF | |
| IL186845A0 (en) | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors | |
| IL186526A0 (en) | Substituted amide derivatives as protein kinase inhibitors | |
| HK1105631A1 (en) | Substituted 2-alkyl quinazolinone derivatives as parp inhibitors | |
| PT1846394E (pt) | Derivados de pirazolilaminopiridina úteis como inibidores da quinase | |
| IL187310A0 (en) | Bicyclic derivatives as p38 kinase inhibitors | |
| IL198675A0 (en) | Novel aminopyrimidine derivatives as plk1 inhibitors | |
| HK1126204A1 (en) | Substituted bicyclic pyrimidone derivatives | |
| ZA200707141B (en) | Pyridine-2-Carboxamide derivatives as mGluR5 antagonists | |
| HRP20130836T1 (en) | New benzamide derivatives as bradykinin antagonists | |
| IL188027A0 (en) | Bicyclic derivatives as p38 kinase inhibitors | |
| IL192308A0 (en) | Oxazoloisoquinoline derivatives as thrombin receptor antagonists | |
| IL187410A0 (en) | Quinoline derivatives as nk3 antagonists | |
| SI2004654T1 (sl) | Pirazolopirimidinski derivati za uporabo kot kinazni antagonisti | |
| EP2094704A4 (en) | CIS-CYCLOHEXYL SUBSTITUTED PYRIMIDINONE DERIVATIVES | |
| ZA200800506B (en) | Substituted benzimidazoles as kinase inhibitors | |
| ZA200709732B (en) | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors | |
| PL376691A1 (pl) | Sposób wytwarzania pochodnych N-fenylo-2- pirymidynoamin |